GLIOBLASTOMA MULTIFORME: A REVIEW OF THE ROLE OF A3AR SIGNALING IN TUMOR EVOLUTION
Abstract
Glioblastoma multiforme is a grade IV astrocytoma (WHO), being considered the most common and also the most aggressive. One of the treatment alternatives is the manipulation of adenosine receptors such as A3AR, this manipulation could increase the survival time of these patients. Therefore, the focus of this review is to gather several studies on the ability of the A3AR receptor to regulate cell death, proliferation, immunosuppression and angiogenesis through signaling pathways in GBMs.
Parole chiave
Full Text
PDF (Enlgish) (English)Riferimenti bibliografici
Fuller CE, Jones DTW, Kieran MW. New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. Am Soc Clin Oncol Educ B. 2017;37:753-763. doi:10.14694/edbk_175088
Agnihotri S, Burrell KE, Wolf A, et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz). 2013;61(1):25-41. doi:10.1007/s00005-012-0203-0
Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015;152:63-82. doi:10.1016/j.pharmthera.2015.05.005
Faria MHG, Patrocínio RMS V., Rabenhorst SHB. Astrocitomas: Uma Revisão Abrangente. Arq Bras Neurocir. 2006;25(1):23-33.
Holland EC. Glioblastoma multiforme: The terminator. Proc Natl Acad Sci U S A. 2000;97(12):6242-6244. doi:10.1073/pnas.97.12.6242
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1
Delgado-Martín B, Medina MÁ. Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. Adv Sci. 2020;7(9). doi:10.1002/advs.201902971
Quezada C, Peigñan L, Segura R, et al. Glioblastoma multiforme y estudio de la resistencia a la quimioterapia mediada por transportadores ABC. Rev Med Chil. 2011;139(4):415-424. doi:10.4067/S0034-98872011000400001
Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals. 2013;6(12):1475-1506. doi:10.3390/ph6121475
Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(21):8130.
Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell. 2010;1(7):638-655. doi:10.1007/s13238-010-0078-y
Chen J, Li Y, Yu T-S, et al. A restricted cell population propagates glioblastoma growth following chemotherapy. Nature. 2012;488(7412):522-526. doi:10.1038/nature11287.A
Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: An enigmatic player in cell biology. Pharmacol Ther. 2008;117(1):123-140. doi:10.1016/j.pharmthera.2007.09.002
Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: Translating medicinal chemistry and pharmacology into clinical utility. Chem Rev. 2008;108(1):238-263. doi:10.1021/cr0682195
Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA. Adenosine Receptors in Cancer. Vol 193.; 2009. doi:10.1007/978-3-540-89615-9
Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6(1):1-9. doi:10.1186/s40425-018-0360-8
Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19(6):355-367. doi:10.1016/j.molmed.2013.03.005.CD39
Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Physiol Behav. 2017;176(12):139-148. doi:10.1016/j.physbeh.2017.03.040
Takahashi T, Otsuguro K, Ohta T, Ito S. Adenosine and inosine release during hypoxia in the isolated spinal cord of neonatal rats. Br J Pharmacol. 2010;161(8):1806-1816. doi:10.1111/j.1476-5381.2010.01002.x
Quezada C, Garrido W, Oyarzún C, et al. 5′-Ectonucleotidase Mediates Multiple-Drug Resistance in Glioblastoma Multiforme Cells. J Cell Physiol. 2013;228(3):602-608. doi:10.1002/jcp.24168
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - An update. Pharmacol Rev. 2011;63(1):1-34. doi:10.1124/pr.110.003285
Synnestvedt K, Furuta GT, Comerford KM, et al. By Hypoxia-Inducible Factor-1 Mediates Permeability Changes in Intestinal Epithelia. October. 2002;110(7):993-1002. doi:10.1172/JCI200215337.Introduction
Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta - Biomembr. 2011;1808(5):1400-1412. doi:10.1016/j.bbamem.2010.09.020
Gessi S, Sacchetto V, Fogli E, et al. Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol. 2010;79(10):1483-1495. doi:10.1016/j.bcp.2010.01.009
Torres Á, Erices JI, Sanchez F, et al. Extracellular adenosine promotes cell migration/invasion of Glioblastoma Stem-like Cells through A3 Adenosine Receptor activation under hypoxia. Cancer Lett. 2019;446(January):112-122. doi:10.1016/j.canlet.2019.01.004
Rocha R, Torres Á, Ojeda K, et al. The adenosine A3 receptor regulates differentiation of glioblastoma stem-like cells to endothelial cells under hypoxia. Int J Mol Sci. 2018;19(4):1-12. doi:10.3390/ijms19041228
Torres A, Vargas Y, Uribe D, et al. Adenosine A3 receptor elicits chemoresistance mediated by multiple resistance-associated protein-1 in human glioblastoma stem-like cells. Oncotarget. 2016;7(41):67373-67386. doi:10.18632/oncotarget.12033
Vincenzi F, Targa M, Corciulo C, et al. The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells. PLoS One. 2012;7(6). doi:10.1371/journal.pone.0039317
Abbrachio MP, Brambilla R, Ceruti S, et al. G-Protein-Dependent Activation of Phospholipase C by Adenosine A3 Receptors in Rat Brain. Mol Pharmacol. Published online 1994:4002.
Linden J, Auchampach JA, Jin X, Figler RA. The Structure and Function of A1 and A2B Adenosine Receptors. Life Sci. 1998;62(8):0-5.
Schulte G, Fredholm BB. Human adenosine A1, A(2A), A(2B), and A3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol. 2000;58(3):477-482. doi:10.1124/mol.58.3.477
Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix and diseases of the CNS. Trends Neurosci. 1998;21(2):75-80. doi:10.1016/S0166-2236(97)01169-7
Swapna Asuthkar, Kiran Kumar Velpula, Chandramu Chetty BG, Rao and JS. Epigenetic Regulation of miRNA-211 by MMP-9 Governs Glioma Cell Apoptosis, Chemosensitivity and Radiosensitivity. Oncotarget. 2012;3(11):1439-1454.
Lakka SS, Jasti SL, Gondi C, et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene. 2002;21(36):5601-5608. doi:10.1038/sj.onc.1205646
Uribe D, Torres Á, Rocha JD, et al. Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling. Mol Aspects Med. 2017;55:140-151. doi:10.1016/j.mam.2017.01.009
Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610-622. doi:10.1038/nrn2175
Refback
- Non ci sono refbacks, per ora.
Revista Brasileira de Neurologia e Psiquiatria. ISSN: 1414-0365